News Sentiment

HELP sentiment intelligence

Cybin Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.87 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

+10.1% over one week, +59.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Library helping teachers stock up their classrooms

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 10.1% Price confirming higher
Trend fit Trend inactive 59.8% over four weeks
Fair value -31.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 8
TradingView 6
TradingKey 4
Barron's 3
Simply Wall Street 2
GlobeNewswire 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 19
Analyst action 2
Regulatory and legal 2
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
The University of Chicago Booth School of Business Direct company coverage

How AI Is Helping to Explain Stock-Price Moves

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 17:30
Source
The University of Chicago Booth School of Business
Stock Titan Direct company coverage

Helus Pharma (Nasdaq: HELP) funds late-stage CNS trials with $50M raise

Helus Pharma (Cybin Inc.) reported audited fiscal 2026 results and significant pipeline progress, including a recent $50 million underwritten offering to fund its late-stage CNS programs. The company's cash balance stood at $157.3 million as of March 31, 2026, despite a widened n

Tone
Positive 61/100
Event
Earnings
Published
29 Jun 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

Cybin Inc. (HELP) Form 40-F: 51.63M shares, governance disclosures

Cybin Inc. filed its Annual Report on Form 40-F for the fiscal year ended March 31, 2026, reporting 51,631,804 common shares outstanding and confirming its status as a foreign private issuer and emerging growth company listed on Nasdaq under the symbol HELP. The report includes d

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 11:37
Source
Stock Titan
Simply Wall Street Direct company coverage

Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds

Cybin (HELP) has seen its share price rebound recently after reporting that enrollment in its APPROACH Phase 3 trial for HLP003 in major depressive disorder has surpassed 86%. Despite this short-term improvement, the stock is still down significantly year-to-date and over five ye

Tone
Positive 58/100
Event
Market update
Published
28 Jun 2026 19:09
Source
Simply Wall Street
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cybin Inc. (CYBN) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Cybin Inc. (CYBN) following a significant drop in stock price. This investigation comes after the announcement that CEO Doug Drysdale would be stepping down. The firm encourages stockh

Tone
Neutral 50/100
Event
Regulatory and legal
Published
28 Jun 2026 16:11
Source
The National Law Review
TradingView Direct company coverage

Enterprise value to EBITDA forward of Cybin, Inc. – NEO:HELP

This page provides financial information for Cybin, Inc. (NEO:HELP), with a specific focus on its enterprise value to EBITDA forward metric. It also lists various TradingView features and services related to market data, analysis tools, and community engagement.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 23:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Cybin, Inc. – MUN:R7E

This article provides financial information for Cybin, Inc. (R7E) on the Munich Stock Exchange, specifically focusing on its forward price-to-sales ratio. It indicates that the market is currently closed with no trades recorded.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:40
Source
TradingView
TradingView Direct company coverage

Cybin Inc expected to post a loss of 93 cents a share - Earnings Preview

Cybin Inc. is projected to report a loss of 93 cents per share. This information is provided as an earnings preview by Refinitiv. The article is a concise report highlighting upcoming financial expectations for the company.

Tone
Negative 38/100
Event
Earnings
Published
26 Jun 2026 19:40
Source
TradingView
Market source Direct company coverage

Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?

Cybin's investment narrative is re-evaluated following two key developments: Helus Pharma's HLP003 Phase 3 trial for major depressive disorder surpassing 86% enrollment, and Cybin Inc. completing a US$50 million equity raise. These events highlight clinical progress and near-term

Tone
Positive 67/100
Event
Market update
Published
26 Jun 2026 19:09
Source
Market source
Simply Wall Street Direct company coverage

Cybin (HELP) Is Up 28.9% After HLP003 Phase 3 Enrollment Surpasses 86% in MDD Trial

Cybin's stock (HELP) surged 28.9% following an announcement that enrollment for its HLP003 Phase 3 trial for Major Depressive Disorder has surpassed 86%. This progress is significant for the company's investment narrative, which relies on the approval and adoption of psychedelic-

Tone
Positive 67/100
Event
Regulatory and legal
Published
26 Jun 2026 12:40
Source
Simply Wall Street
Helus Pharma Direct company coverage

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering - Thu, 06/25/2026 - 09:28

Helus Pharma™ has completed its previously announced underwritten offering, raising US$50 million through the sale of 10,309,280 common shares at US$4.85 each. The pharmaceutical company intends to utilize these net proceeds to advance its clinical programs, HLP003, HLP004, and H

Tone
Positive 65/100
Event
Market update
Published
25 Jun 2026 17:40
Source
Helus Pharma
Stock Titan Direct company coverage

Helus Pharma (Nasdaq: HELP) raises US$50M to fund NSA pipeline

Helus Pharma, operating as Cybin Inc., successfully closed an underwritten offering, raising US$50 million through the sale of 10,309,280 common shares at US$4.85 per share. The company plans to allocate the net proceeds to advance its novel serotonergic agonist (NSA) pipeline, s

Tone
Positive 65/100
Event
Market update
Published
25 Jun 2026 15:12
Source
Stock Titan
GlobeNewswire Direct company coverage

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma™ has completed its US$50 million underwritten offering of 10,309,280 common shares at US$4.85 per share. The proceeds will fund the development of its HLP003, HLP004, and HLP005 programs for major depressive disorder and generalized anxiety disorder, and for general

Tone
Positive 66/100
Event
Market update
Published
25 Jun 2026 13:12
Source
GlobeNewswire
Stock Titan Direct company coverage

Helus Pharma (HELP) prices US$50M share sale to fund Phase 3 MDD trial

Helus Pharma, operating as Cybin Inc., has priced a US$50 million underwritten equity offering, selling 10,309,280 common shares at US$4.85 each. The proceeds will primarily fund its Phase 3 trial for HLP003 in Major Depressive Disorder (MDD) and other programs. The company also

Tone
Positive 66/100
Event
Market update
Published
25 Jun 2026 10:12
Source
Stock Titan
GlobeNewswire Direct company coverage

Helus Pharma™ Announces US$50 Million Underwritten Offering

Helus Pharma™ announced the pricing of an underwritten offering of 10,309,280 common shares at US$4.85 per share, aiming to raise US$50 million in gross proceeds. The funds will primarily support the progression of its HLP003, HLP004, and HLP005 programs for major depressive diso

Tone
Positive 65/100
Event
Market update
Published
24 Jun 2026 22:10
Source
GlobeNewswire